Alimetry has developed a wearable, non-invasive medical device and software platform for the rapid and detailed diagnosis of a range of gastrointestinal disorders.
The device records stomach electrical activity, sending data to a companion iOS app for real-time symptom tracking. The data is analysed in the cloud and a report provided to clinicians, which greatly reduces the uncertainties and risks currently associated with patient diagnostics.
Amaroq Therapeutics, a new biotech start-up spun out of the University of Otago, is advancing its programs to develop next-generation RNA therapy to target cancer.
The Amaroq Therapeutics team, led by Chief Scientific Officer and founder, Dr Sarah Diermeier, are exploring the use of lncRNA molecules as therapeutic targets and diagnostic markers in the treatment of cancer. They will be working on therapies to treat common cancers such as breast, colorectal and liver cancer.
The study of long non-coding RNAs (IncRNAs), often referred to as 'dark matter' of the genome, are molecules naturally present in cells. They have become a focus of research globally as they can act as key cell regulators despite not coding for proteins.
Avalia’s proprietary vaccine and immunotherapy platform generates robust and targeted immune responses for the prevention and treatment of infectious disease and cancer.
Avalia's platform is patent protected with over 25 granted patents around the world.
Avalia’s lead program is targeting a cure for the 250 million people living with chronic hepatitis B infection – a liver-related disease. With no effective cure, chronic hepatitis B can lead to cirrhosis, liver cancer and requirement for liver transplants, and globally results in 1 million deaths per annum.
Through collaborations, Avalia is also developing a pipeline of treatment vaccines and new immune-targeting treatments for cancer.
Chitogel is a medical device company with an advanced manufacturing facility based in Lower Hutt. They supply medical kits that optimse the wound healing environment and significantly improve patient outcomes following sinus surgery.
Originating from University of Otago research, Chitogel's developments are backed by over 10 years of research and clinical evidence, including 17 published studies and scientific papers and the observation of successful outcomes of a diverse range of sinus surgeries.
Ferronova is a cancer diagnostics company, developing surgical oncology tracer systems for improving the staging of complex cancers.
More than 40% of people will be diagnosed with cancer during their lifetime. Successful cancer treatment relies on accurate staging of how far, and where cancer has spread from a primary tumour.
Ferronova's injectable magnetic and fluorescent tracers are designed to less invasively, more quickly, and more accurately map the pathways of the spread of cancer to lymph nodes.
InsituGen has developed a new testing platform for the detection of anabolic drugs in biological samples. The bioassays can be used to detect steroidal targets in animals, human athletes, and food sources such as nutritional supplements.
The initial product focus for its technology is directed towards detecting doping in the horseracing industry and trials in the horse racing industry in Australasia are currently demonstrating the superior value of their testing approach.
The product has also been tailored to be used in the camel racing industry in the Middle East. Customer trials are ongoing and yielding good results.
Mekonos is focused on improving how drugs are delivered to patients, and enabling highly-potent cell therapy approaches.
This is being achieved with their custom-developed silicon chips, each holding thousands of individually moving nano-needles, which are used to carry drug cargo that can be injected into the nucleus of cells. This helps to improve uptake and reducing waste.
The initial concept originated from a PhD project at the University of Canterbury. It quickly became clear that the company needed to be in the US, where major innovations in cell therapy are being developed.